Status:
COMPLETED
AEG35156 and Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Solid Tumors
Lead Sponsor:
NCIC Clinical Trials Group
Conditions:
Unspecified Adult Solid Tumor, Protocol Specific
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. AEG35156 may help doc...
Detailed Description
OBJECTIVES: Primary * Determine the maximum tolerated dose and define a recommended phase II dose of AEG35156 in combination with docetaxel in patients with locally advanced, metastatic, or recurren...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Histologically confirmed solid tumor
- Locally advanced, metastatic, or recurrent disease that is refractory to standard curative therapy or for which no curative therapy exists
- Clinically and/or radiologically documented disease
- Treatment with single-agent docetaxel is a reasonable treatment option
- No newly diagnosed CNS metastases
- Previously treated and stable (≥ 6 months) intracranial disease allowed
- PATIENT CHARACTERISTICS:
- ECOG performance status 0-2
- Life expectancy ≥ 12 weeks
- Absolute granulocyte count ≥ 1,500/mm³
- Platelet count ≥ 100,000/mm³
- PT or INR and PTT normal
- Creatinine normal
- Bilirubin normal
- AST and ALT ≤ 1.5 times upper limit of normal (ULN)
- Gamma-glutamyl transferase ≤ 3 times ULN
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- No underlying serious illness or medical condition that might be aggravated by treatment or might interfere with study treatment, including, but not limited to, the following:
- Serious uncontrolled infection
- Significant cardiac dysfunction
- Significant neurological disorder that would impair the ability to obtain informed consent
- No known bleeding disorders
- No prior serious allergic reaction to taxane (paclitaxel or docetaxel)
- No pre-existing peripheral neuropathy ≥ grade 2
- PRIOR CONCURRENT THERAPY:
- More than 4 weeks since prior chemotherapy and recovered
- At least 2 weeks since prior hormonal therapy or immunotherapy
- At least 4 weeks since prior external-beam radiotherapy to \< 30% of marrow-bearing areas
- Low-dose, nonmyelosuppressive radiotherapy allowed
- At least 2 weeks since prior surgery and recovered
- More than 4 weeks since prior investigational agents or new anticancer therapy
- No prior nephrectomy
- No other concurrent chemotherapy
- No concurrent radiotherapy
- Small-volume, non-myelosuppressive palliative radiotherapy allowed
- No other concurrent experimental drugs or anticancer therapy
- No concurrent therapeutic dose anticoagulant therapy
- Non-therapeutic dose anticoagulant therapy (i.e., 1 mg daily oral warfarin) allowed
Exclusion
Key Trial Info
Start Date :
July 27 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 6 2012
Estimated Enrollment :
27 Patients enrolled
Trial Details
Trial ID
NCT00372736
Start Date
July 27 2006
End Date
January 6 2012
Last Update
August 4 2023
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
BCCA - Vancouver Cancer Centre
Vancouver, British Columbia, Canada, V5Z 4E6
2
Univ. Health Network-Princess Margaret Hospital
Toronto, Ontario, Canada, M5G 2M9
3
McGill University - Dept. Oncology
Montreal, Quebec, Canada, H2W 1S6